154 related articles for article (PubMed ID: 25380635)
1. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
Peethambaram PP; Hartmann LC; Jonker DJ; de Jonge M; Plummer ER; Martin L; Konner J; Marshall J; Goss GD; Teslenko V; Clemens PL; Cohen LJ; Ahlers CM; Alland L
Invest New Drugs; 2015 Apr; 33(2):321-31. PubMed ID: 25380635
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
Abraham J; Agrawal M; Bakke S; Rutt A; Edgerly M; Balis FM; Widemann B; Davis L; Damle B; Sonnichsen D; Lebwohl D; Bates S; Kotz H; Fojo T
J Clin Oncol; 2003 May; 21(9):1866-73. PubMed ID: 12721265
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
Mani S; McDaid H; Hamilton A; Hochster H; Cohen MB; Khabelle D; Griffin T; Lebwohl DE; Liebes L; Muggia F; Horwitz SB
Clin Cancer Res; 2004 Feb; 10(4):1289-98. PubMed ID: 14977827
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors.
Zhang P; Sun M; Qiu R; Tang L; Dou G; Xu B
Cancer Chemother Pharmacol; 2011 Oct; 68(4):971-8. PubMed ID: 21305287
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
Gadgeel SM; Wozniak A; Boinpally RR; Wiegand R; Heilbrun LK; Jain V; Parchment R; Colevas D; Cohen MB; LoRusso PM
Clin Cancer Res; 2005 Sep; 11(17):6233-9. PubMed ID: 16144926
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.
Sessa C; Perotti A; Lladò A; Cresta S; Capri G; Voi M; Marsoni S; Corradino I; Gianni L
Ann Oncol; 2007 Sep; 18(9):1548-53. PubMed ID: 17761711
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
11. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
Smaletz O; Galsky M; Scher HI; DeLaCruz A; Slovin SF; Morris MJ; Solit DB; Davar U; Schwartz L; Kelly WK
Ann Oncol; 2003 Oct; 14(10):1518-24. PubMed ID: 14504052
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
Bröker LE; de Vos FY; van Groeningen CJ; Kuenen BC; Gall HE; Woo MH; Voi M; Gietema JA; de Vries EG; Giaccone G
Clin Cancer Res; 2006 Mar; 12(6):1760-7. PubMed ID: 16551860
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
Monk JP; Villalona-Calero M; Larkin J; Otterson G; Spriggs DS; Hannah AL; Cropp GF; Johnson RG; Hensley ML
Invest New Drugs; 2012 Aug; 30(4):1676-83. PubMed ID: 21826439
[TBL] [Abstract][Full Text] [Related]
19. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]